The groundbreaking success of the copyright undeniably reshaped the pharmaceutical landscape, but placing funds in companies primarily reliant here on unbranded versions presents a challenging picture. While early profits were significant, the end of patents and the rise of less expensive alternatives have diminished market share. Consequently, a t